ID   MTA
AC   CVCL_3032
DR   BioSample; SAMN03472801
DR   cancercelllines; CVCL_3032
DR   Cell_Model_Passport; SIDM01868
DR   DepMap; ACH-001132
DR   JCRB; IFO50513
DR   Wikidata; Q54906980
RX   PubMed=10222657;
RX   PubMed=16827800;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: ~1.5 days (Note=Lot 03262004), ~69 hours (Note=Lot 02122015) (JCRB=IFO50513).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Unspecified (DepMap=ACH-001132).
CC   Omics: Deep exome analysis.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): JCRB=IFO50513
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 11
ST   D16S539: 9,12
ST   D5S818: 10,11
ST   D7S820: 10,11
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 18,19
DI   NCIt; C82217; Natural killer cell lymphoblastic leukemia/lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   58Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 21
//
RX   PubMed=10222657;
RA   Emi N., Abe A., Kasai M., Kohno A., Tanimoto M., Kimura H.,
RA   Kawashima K., Ito M., Mori N., Saito H.;
RT   "CD4- and CD56-positive T-cell line, MTA, established from natural
RT   killer-like T-cell leukemia/lymphoma.";
RL   Int. J. Hematol. 69:180-185(1999).
//
RX   PubMed=16827800; DOI=10.1111/j.1349-7006.2006.00226.x;
RA   Liu A., Takakuwa T., Luo W.-J., Fujita S., Aozasa K.;
RT   "Alterations in ATR in nasal NK/T-cell lymphoma and chronic active
RT   Epstein-Barr virus infection.";
RL   Cancer Sci. 97:605-610(2006).
//